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Background: Both bone morphogenetic proteins (BMPs) and histone deacetylases (HDACs) have previously been
established to play a role in the development of the three major cell types of the central nervous system: neurons,
astrocytes, and oligodendrocytes. We have previously established a connection between these two protein families,
showing that HDACs suppress BMP-promoted astrogliogenesis in the embryonic striatum. Since HDACs act in the
nucleus to effect changes in transcription, an unbiased analysis of their transcriptional targets could shed light on
their downstream effects on BMP-signaling.
Results: Using neurospheres from the embryonic striatum as an in vitro system to analyze this phenomenon, we
have performed microarray expression profiling on BMP2- and TSA-treated cultures, followed by validation of the
findings with quantitative RT-PCR and protein analysis. In BMP-treated cultures we first observed an upregulation of
genes involved in cell-cell communication and developmental processes such as members of BMP and canonical
Wnt signaling pathways. In contrast, in TSA-treated cultures we first observed an upregulation of genes involved in
chromatin modification and transcription. Interestingly, we could not record direct changes in the protein levels of
canonical members of BMP2 signaling, but we did observe an upregulation of both the transcription factor STAT3
and its active isoform phospho-STAT3 at the protein level.
Conclusions: STAT3 and SMAD1/5/8 interact synergistically to promote astrogliogenesis, and thus we show for the
first time that HDACs act to suppress BMP-promoted astrogliogenesis by suppression of the crucial partner STAT3.Background
During development of the central nervous system a variety
of different cell-types need to be generated. The three
major brain cell types, neurons, astrocytes and oligodendro-
cytes, arise from neural progenitor cells. Neurons are the
first cell type to be generated, starting soon after formation
of the neuroectoderm at mid-gestation, and astrocytes and
oligodendrocytes are born only shortly before birth and
continuing into the postnatal period. The mechanisms by
which neural stem cells transition from a neuron- to an
astrocyte-generating progenitor are only partially under-
stood, but secreted growth factors are known to play a role* Correspondence: Kerry.Tucker@urz.uni-heidelberg.de; wolfl@uni-hd.de
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reproduction in any medium, provided the orin this process. For example, multiple bone morphogenetic
proteins (BMPs), members of the TGF-beta super family,
and their receptors are abundantly expressed in the devel-
oping brain, starting as early as 8.75 days post coitum
(E8.75) [1-4]. In vitro, BMPs were shown to promote the
generation of astrocytes [5], and in vivo, shown to promote
astrocyte formation at the expense of oligodendrocytes
[6,7]. In particular, BMP2/4 are known to enhance astro-
gliogenesis and to inhibit neurogenesis through induction
of the inhibitory basic helix-loop-helix transcription factor
genes Id1, Id3, and Hes5 which antagonize the proneural
gene Ngn1 [8]. However, BMP2/4 has also been shown to
promote neuronal differentiation in the cortex [9,10].
It is becoming increasingly evident that the regulation of
genes involved in brain development occurs not just at the
level of the expression of activating and inhibiting tran-
scription factors, but also at the epigenetic level, in the co-
valent modification of chromatin [11]. Core histones can betd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to name just the best-known chemical groups involved, and
these small moieties regulate the chromatin structure and
subsequent gene expression. Acetylation of the ε-amino
groups of lysine residues in the amino-termini of core
histones by histone acetyltransferases (HATs) leads to relax-
ation of chromatin conformation, resulting in transcrip-
tional activation [12]. Conversely, histone deacetylation
increases chromatin compaction and thereby reduces
accessibility of transcription factors to the DNA. Deacetyla-
tion is catalyzed by histone deacetylases (HDAC), a large
group of enzymes which are classified, based upon their
domain structure and sequence homology, into four gene
families [13]. Class I HDACs (HDAC1, -2, -3, and −8) are
orthologs of the yeast transcriptional regulator RPD3 and
are primarily localized in the nucleus. Class II HDACs
(HDAC4, -5, -6, -7, -9, and −10) are homologous to the
yeast HDA1 protein and can shuttle between the nucleus
and the cytoplasm. Structurally and mechanistically differ-
ent classes of HDACs are the sirtuins (Sirt1-7), also known
as Class III HDACs. They are NAP-depended enzymes
homologous to yeast Sir2 (silent information regulator 2)
[14]. HDAC11 is the only histone deacetylase categorized
to HDAC class IV [15].
It has been previously shown that histone acetylation
is crucial for the dynamic regulation of gene expression
during differentiation processes. Especially, skeletal and
cardiac myogenesis have been intensively studied [16].
Recent publications strongly suggest that HDACs are
also important for the development of the nervous sys-
tem. A large number of different HDACs are expressed
in the developing brain, suggesting specific roles for in-
dividual HDACs in neural development [17]. HDACs
have been shown to be involved in the birth and matur-
ation of oligodendrocytes in the rat, mouse, and in
zebrafish [18-21]. It has also been shown that HDACs
play an important role in the control of neurogenesis
and astrogliogenesis. Especially HDAC1 and HDAC2
have been reported in the regulation of distinct linage
specification in developing brain. During neuronal devel-
opment HDAC1 and 2 are both expressed in stem and
progenitor cells. In post-mitotic neurons only HDAC2
expression can be detected, while HDAC1 is only
expressed in glia [22]. Deletion of both HDAC1 and 2
results in major abnormalities in cortical, hippocampal
and cerebellar development, whereas an individual dele-
tion of HDAC1 or HDAC2 has no effect. Interestingly,
deletion of HDAC1 and HDAC2 almost completely
blocks the neuronal differentiation, but does not influ-
ence astrogliogenesis [23].
Trichostatin A (TSA), a well-established reversible in-
hibitor of class I and II HDACs [24], has been reported to
induce cell growth arrest, apoptosis and differentiation in
tumor cells [25]. The treatment of adult neural progenitorcells with HDAC inhibitors causes antiproliferative effects
and induces neuronal differentiation, whereas the differen-
tiation of astrocytes or oligodendrocytes is simultaneously
not induced [26]. In a previous study we could demon-
strate that inhibition of class I and II HDACs with TSA
leads to an increase in neurogenesis in the developing
cortex, but results in a dramatic reduction in neurogenesis
in the medial and lateral ganglionic eminences (GE) of the
embryonic forebrain [27]. The reduction in neurogenesis
in GE-derived neural precursors was accompanied by an
increase in the production of immature astrocytes. We
could further demonstrate that treatment with recombin-
ant BMP2 increased the production of astrocytes in neural
precursors derived from GE, whereas no significant in-
crease in astrogliogenesis was detected in cortical neural
precursor cells. A co-treatment with TSA and noggin, a
BMP2 inhibitor, or with Alk3-ECD, a recombinant protein
that contains the extracellular domain of the BMPR1A
receptor, was able to restore the normal levels of neurons
and astrocytes, compared to untreated control samples,
demonstrating a direct connection between HDAC activ-
ity and BMP signaling [27]. In order to investigate the sig-
naling pathways involved in the differentiation of GE
derived neural precursors upon TSA and BMP2 treat-
ment, we performed gene expression profiling and protein
analysis from BMP2 or TSA treated neural precursor cells
derived from GE at different time points. Here, we show
that BMP2 and TSA influence neurogenesis in a related
manner. We demonstrate that in the early response to
BMP2 and TSA treatment, different cohorts of functional
gene groups are activated or repressed, although the
downstream biological effects are closely related. We fur-
ther characterized individual genes picked up by the
microarrays at both mRNA and protein levels.
Results
In vitro differentiation of forebrain derived
neurosphere cultures
We used neurosphere cultures to generate a uniform
population of neural precursors directly from the medial
and lateral ganglionic eminences of E15.5 C57BL/6 mice
[28]. After 7 days neurospheres were dissociated, plated
out as a monolayer, and differentiated according to stan-
dard protocols [29]. During differentiation FGF2 was
withdrawn after 2.5 days, whereas the treatment with
TSA or BMP2 started 1.5 days after plating (Figure 1A).
Cultures were allowed to differentiate for an add-
itional 4.5 days after FGF2 withdrawal and then
stained with immunocytofluorescence for standard
markers indicating the birth of newborn neurons
(TuJ1), astrocytes (GFAP), and oligodendrocytes (O4)
(Figure 1B,C). As reported previously [27], both TSA
as well as BMP2 treatment suppressed neurogenesis
and boosted astrogliogenesis, as indicated by the
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Figure 1 (See legend on next page.)
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Figure 1 Neurosphere cultures and immunocytofluorescence. For in vitro differentiation cells from the basal ganglia of 15.5 dpc C57BL/6
mice were cultured in neurospheres and dissociated after 7 days. FGF2 was withdrawn after 2.5 days and treatment started 1.5 days after plating.
Cells were treated with TSA (10, 25 or 50nM) or BMP2 (10 ng/ml). RNA and proteins were isolated after 6, 12 and 24 h (A). For
immunocytofluorescence (B,C), cultures were treated with vehicle (CTL), 50nM trichostatin A (TSA), 10 ng/ml recombinant BMP2 (BMP2), or both
reagents (BMP2/TSA) for 24 hours before bFGF withdrawal. Cultures were fixed after 4.5 additional days and stained with the following
antibodies: TuJ1 (B, green) to label newborn neurons, anti-GFAP (B, red) to label newborn astrocytes, or O4 (C, red, indicated with arrows) to label
newborn oligodendrocytes. DAPI (blue) was used to stain nuclei. Scale bar = 50 (B) and 100 (C) μm.
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positive astrocytes in the cultures (Figure 1B). Simul-
taneous treatment with both TSA and BMP2 showed
a similar effect (Figure 1B). As reported previously
[27], both TSA as well as BMP2 treatment suppressed



















Figure 2 Western Blot of linage specific markers. Proteins were extract
cultures 24 h (A).and 7 days (B) after treatment. Western Blot for Plp, Mbp,
were quantified and normalized to β-Actin (C). The results shown are onejudged by their relative numbers as well as the elab-
oration of their processes (Figure 1C).
In addition western blot analysis of astrocyte and
oligodendrocyte specific proteins 24h (h) and 7 days after
treatment with TSA or BMP2 were performed (Figure 2).
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Whereas the protein levels of GFAP was rather unchanged
24 h after treatment with TSA and BMP2 (Figure 2A), a
strong increase of GFAP could be detected 7 days after
treatment (Figure 2B), indicating that the treatment with
TSA and BMP2 led to an increase in astrogliogenesis dur-
ing differentiation of neurosphere cultures. The oligo-
dendrocyte markers Plp (proteolipid protein) and Mbp
(myelin basic protein) [30] were less clearly regulated on
the protein level at both time points, but a small decrease
of both markers could be detected 7 days after treatment
(Figure 2).
Microarray analysis of differentiating
neurosphere cultures
RNA samples and protein lysates were prepared 6, 12, and
24 h after treatment. We performed gene expression pro-

























































Figure 3 Gene expression profiling of BMP2 and TSA treated neurosp
2-fold and absolute difference >100, comparing treated and control sampl
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regulated genes are indicated in the diagram, the total number of regulate
regulated genes between TSA 6 h and BMP2 6 h (B), TSA 24 h and BMP2 6
BMP2 6 h and BMP2 24 h (F) and TSA 6 h and TSA 24 h (G) are illustrated.
analysis. Red and green depict at least two-fold increase or decrease in exp
at the right side of the cluster plot. Clusters, grouping genes downregulate
individual main sub-cluster of hierarchical cluster analysis were functional aGenChip 420 2.0. The raw data was analyzed using dChip
(DNA-chip analyzer) software [31]. Genes were consid-
ered to be significantly regulated if their expression had
changed more than two-fold and had exceeded a minimal
absolute difference of 100 comparing treated and mock-
treated cells with a confidence greater than 90%. Using
these conditions 220 genes exhibited a differential expres-
sion in BMP2-treated cells after 6 h, and 573 genes were
differentially regulated after 24 h (Figure 3A-F). TSA treat-
ment led to 917 differentially-expressed genes after 6 h
and 982 after 24 h treatment (Figure 3A-F). The top 25
genes regulated after TSA or BMP2 treatment are listed in
the Additional file 1: Table S1–S4.
To identify an overlap of regulated genes within TSA
and BMP2 treatments, two-set Venn analyses were
performed, intersecting TSA 6 h, TSA 24 h, BMP2 6 h
and BMP2 24 h experimental sets, respectively. The inter-
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regulated genes for each treatment condition are depicted
in the diagrams, while individual genes within the inter-
section are listed in the Additional file 1: Table S5–S10.
Comparing these two-set Venn diagrams, it could be
observed that the majority of regulated genes was unique
for one treatment; only a smaller number of genes was
located within the intersections between the two experi-
mental sets. The largest intersection of regulated genes
was detected between TSA 6 h and TSA 24 h (Figure 3F).
The intersection between the BMP2 6 h and 24 h experi-
ments was marginally smaller; however more than half of
the genes regulated after 6 h overlap with genes regulated
after 24 h (Figure 3E). Comparing the Venn analyses of
TSA- and BMP2-treated samples at the two different time
points an increased number of co-regulated genes could
be detected from 6 h to 24 h (Figure 3A-D). Whereas only
27 genes were regulated in both BMP2 6 h and TSA 6 h
(Figure 3A), the number of regulated genes in BMP2 24 h
and TSA 24 h experimental sets increased 6-fold
(Figure 3D). This increased number of regulated genes in
the intersection of TSA and BMP2 treated sample after
24 h mainly resulted from an increase of regulated genes
in the BMP2 24 h sample, even if the number of regulated
genes in BMP2 24 h experiment is only 2.6-fold higher
than in BMP2 6 h experiment (Figure 3A, 3D).
In addition to the two-set Venn analyses, the overlap of
genes regulated in all four sets of experiment and in three
out of four sets was additionally analyzed. A summary of
these genes is listed in Table 1, indicating their fold-change
in each treatment. Remarkably, only eight genes were sig-
nificantly altered after the treatment with BMP2 and TSA
at both time points: Gpr17 (G protein-coupled receptor
17), Lims2 (LIM and senescent cell antigen like domains 2),
Bcas1 (breast carcinoma amplified sequence 1), Ptpre
(protein tyrosine phosphatase, receptor type, E), Afap1l2
(actin filament associated protein 1-like 2), Dll3 (delta-
like 3), G0s2 (G0/G1 switch gene 2), Gpd1 (glycerol-3-
phosphate dehydrogenase1). 65 genes were regulated in
at least three out of four experimental sets. Most of
these genes were regulated in the same direction when
treated with BMP2 or TSA, and only a few genes exhib-
ited an opposed expression. Smad7 (MAD homolog 7
(Drosophila)), Papss2 (3′-phosphoadenosine 5′-phospho-
sulfate synthase 2), Fam19a2 (family with sequence simi-
larity 19, member A2), Cadps (Ca2+-dependent secretion
activator), Car8 (carbonic anhydrase 8) and Efhd1 (EF
hand domain containing 1) are examples for an opposed
regulation of expression comparing BMP2- and TSA-
treated samples. Smad7, Papss2, Fam19a2, and Cadps
expression was suppressed after TSA treatment but
induced after treatment with BMP2, whereas Car8 and
Efhd1 expression was regulated in a reverse fashion
(Table 1).In accordance with the results from the two-set Venn
analysis, the number of co-regulated genes was increased
when the BMP2 24 h time point was included in the
intersection analysis (Table 1). However, among these
genes, the expression of only a few was significantly
stronger regulated after 24 h than after 6 h of both TSA
and BMP2 treatment. Especially, the expression of Gpr17,
Lims2, Bcas1, BMP4, Enpp6 (ectonucleotide pyropho-
sphatase/phosphodiesterase 6) and Gm98 (predicted
gene 98) was significantly reduced in 24 h compared to
6 h experiments. It should be mentioned that, among
those genes regulated by BMP2 6 h and 24 h and TSA
24 h, several genes known to be involved in BMP2/4 sig-
naling, like Bmp4, Smad7, Fst (Follistatin) and Bambi
(BMP and activin membrane-bound inhibitor, homolog
(Xenopus laevis)) were detected.
We also performed hierarchical clustering of the mi-
croarray data using the clustering option of dChip [31]
to illustrate the overall relationship between regulated
genes (Figure 3G). All genes regulated in at least one of
the analyzed conditions were included using the same
stringent criteria as above (twofold change; euclidean
distance 100). The clustering led to two major clusters,
one including genes upregulated, the other including
genes downregulated upon either treatment. Genes up-
regulated after each treatment were further divided into
three sub-clusters, grouping genes upregulated after treat-
ment with (i) BMP2 or (ii) TSA alone or (iii) both BMP2
and TSA. Each sub-cluster could be subdivided into
smaller groups of genes that represent individual time
points. Within the cluster of downregulated genes, also
three sub-clusters could be distinguished, containing
genes downregulated after treatment with (i) BMP2 or
(ii) TSA alone (clustered in the middle of Figure 3G)
and (iii) downregulated after both treatments.
To investigate the specific biological functions of co-
regulated groups of genes, we used the DAVID Database
(Database for Annotation, Visualization and Integrated
Discovery) for functional annotation of clustered genes
[32,33]. Functional annotation clustering allows the clas-
sification of regulated genes according to their functional
relevance. Each of the six sub-clusters obtained in the
hierarchical clustering was independently annotated. An
overview of the various functional categories for the six
sub-clusters is shown in Table 2, Gene Ontology annota-
tions of individual clusters can be found in Additional
file 1: Tables S11-S21. Strong differences in the func-
tional categories arose upon comparison of up- and down-
regulated gene clusters. Within the gene cluster including
genes upregulated after TSA treatment, functional cat-
egories like antigen processing, metabolism, cell mem-
brane and cell adhesion were enriched (Additional file 1:
Table S11-S14), the cluster of downregulated genes in-
cluded functional categories related to chromosome
Table 1 Genes significantly regulated upon TSA and BMP2 treatment
Gene name Gene name
symbol
BMP2 TSA
6 h 24 h 6 h 24 h
G protein-coupled receptor 17 Gpr17 −3.13 −30.90 −6.80 −80.21
ectonucleotide pyrophosphatase/phosphodiesterase 6 Enpp6 −1.99 −23.08 −3.93 −30.02
LIM and senescent cell antigen like domains 2 Lims2 −2.80 −24.72 −4.61 −27.27
plexin B3 Plxnb3 −1.12 −8.69 −4.61 −26.64
serine/arginine-rich protein specific kinase 3 Srpk3 −1.22 −7.54 −6.01 −26.60
galactose-3-O-sulfotransferase 1 Gal3st1 −1.01 −8.92 −4.96 −18.20
breast carcinoma amplified sequence 1 Bcas1 −2.80 −24.38 −9.53 −17.36
bone morphogenetic protein 4 Bmp4 −9.01 −34.17 −3.25 −15.47
S100 protein. beta polypeptide. neural S100b 1.19 −4.14 −3.54 −14.71
ELOVL family member 7. elongation of long chain fatty acids Elovl7 −1.21 −6.57 −3.33 −14.34
breast carcinoma amplified sequence 1 Bcas1 −1.55 −11.02 −2.93 −13.89
RAB33A. member of RAS oncogene family Rab33a −1.50 −9.41 −7.10 −13.66
SRY-box containing gene 10 Sox10 −1.28 −6.73 −2.81 −13.51
protein kinase C. theta Prkcq −2.52 −4.70 −11.82 −12.45
tubulin. beta 4 Tubb4 −1.68 −5.93 −4.74 −12.31
Down syndrome cell adhesion molecule Dscam −2.02 −4.85 −3.70 −11.67
oligodendrocyte myelin glycoprotein Omg −1.38 −2.61 −11.48 −9.86
four and a half LIM domains 2 Fhl2 −1.11 −11.15 −6.79 −9.48
glycerol-3-phosphate dehydrogenase 1 Gpd1 −2.93 −8.02 −2.50 −7.87
chimerin (chimaerin) 2 Chn2 −1.41 −6.46 −5.09 −7.68
protein tyrosine phosphatase. receptor type. E Ptpre −18.37 −16.45 −2.53 −7.19
Down syndrome cell adhesion molecule-like 1 Dscaml1 −3.25 −2.48 −3.19 −5.91
phosphatase and actin regulator 3 Phactr3 −3.18 −6.73 −1.86 −5.81
MAD homolog 7 (Drosophila) Smad7 4.51 6.86 −3.24 −5.69
family with sequence similarity 19. member A2 Fam19a2 3.13 1.03 −3.10 −5.38
leucine rich repeat transmembrane neuronal 1 Lrrtm1 −1.90 −4.49 −7.54 −5.20
solute carrier family 24 member 3 Slc24a3 −2.44 −1.87 −3.79 −4.96
delta-like 3 (Drosophila) Dll3 −4.14 −3.64 −3.32 −4.49
shroom family member 2 Shroom2 −1.39 −2.78 −3.69 −4.46
WAS/WASL interacting protein family member 1 Wipf1 −1.20 −2.68 −3.89 −4.20
actin filament associated protein 1-like 2 Afap1l2 −3.47 −3.68 −4.84 −4.16
seizure related 6 homolog like Sez6l −3.30 −2.91 −2.92 −4.16
proline rich region 18 Prr18 −1.71 −3.35 −6.74 −4.09
striatin. calmodulin binding protein Strn −1.55 −2.35 −2.94 −4.07
G0/G1 switch gene 2 G0s2 −3.89 −5.35 −6.74 −4.02
cytoplasmic FMR1 interacting protein 2 Cyfip2 −2.12 −4.22 −2.53 −3.79
platelet derived growth factor alpha Pdgfa −2.27 −5.57 −4.54 −3.59
3'-phosphoadenosine 5'-phosphosulfate synthase 2 Papss2 6.90 10.70 −2.50 −3.34
dedicator of cytokinesis 9 Dock9 −1.86 −5.59 −2.63 −3.28
zinc finger protein 365 Zfp365 −3.75 −5.30 −2.43 −3.23
ring finger protein 122 Rnf122 −2.05 −2.76 −2.63 −2.92
SH3-domain binding protein 4 Sh3bp4 −3.26 −4.35 −1.82 −2.79
erythrocyte protein band 4.1 Epb4.1 −2.43 −3.67 −1.30 −2.55
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Table 1 Genes significantly regulated upon TSA and BMP2 treatment (Continued)
TNF receptor associated factor 4 Traf4 −3.54 −4.89 −2.20 −2.45
myelocytomatosis oncogene Myc −2.37 −4.17 −3.82 −1.70
Ca2 +−dependent secretion activator Cadps 2.90 4.96 −2.52 −1.39
GS homeobox 1 Gsx1 −2.52 −5.17 −4.86 −1.20
leucine rich repeat and fibronectin type III. extracellular 1 Elfn1 −4.08 −6.57 −2.81 −1.06
myosin regulatory light chain interacting protein Mylip 7.66 4.10 3.47 1.55
tumor necrosis factor receptor superfamily. member 12a Tnfrsf12a 9.04 10.10 7.39 1.87
carbonic anhydrase 8 Car8 −2.65 −6.46 2.65 2.06
epidermal growth factor receptor Egfr −4.15 −7.93 −1.95 2.73
BMP and activin membrane-bound inhibitor.
homolog (Xenopus laevis)
Bambi 3.46 3.60 2.61 3.41
follistatin Fst 16.56 19.63 1.55 4.18
Rho GTPase activating protein 29 Arhgap29 2.69 8.01 5.84 4.35
DIRAS family. GTP-binding RAS-like 2 Diras2 12.12 99.94 1.09 4.51
aquaporin 11 Aqp11 1.66 5.08 3.24 4.61
Kruppel-like factor 4 (gut) Klf4 5.39 13.51 7.94 4.74
regulator of G-protein signalling 10 Rgs10 1.01 3.25 3.20 6.39
EF hand domain containing 1 Efhd1 −1.52 −5.45 3.22 6.77
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum
protein retention eceptor 3
Kdelr3 1.62 7.32 11.15 6.87
zinc finger. CCHC domain containing 12 Zcchc12 1.95 4.24 8.50 9.35
family with sequence similarity 70. member A Fam70a 7.28 13.35 2.99 16.08
predicted gene 98 Gm98 −2.39 −13.78 −4.13 −20.43
Genes significantly regulated upon all treatments (printed in bold) and three out of four treatments are summarized.
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posttranslational processes (Additional file 1: Table S15).
In the case of BMP2 treatment, the gene cluster of upre-
gulated genes was enriched for functional categoriesTable 2 Overview of the functional categories for the six
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• adhesion, extracellular matrix • differentiation, development
• neurogenesisassociated with cell communication, cell membrane,
extracellular matrix, differentiation and development
(Additional file 1: Table S18-S20). Genes downregulated
after BMP2 treatment were enriched in the functional
categories related to cell communication and signal trans-
duction (Additional file 1: Table S21). The functional
annotation of the sub-cluster containing genes upregu-
lated after both treatments showed an enrichment of
categories related to extracellular matrix and cell adhe-
sion, whereas the sub-cluster of downregulated genes
comprised categories related to differentiation and devel-
opment (Additional file 1: Table S16-S17). As well from
the list of individual genes as from the functional cluster
analysis it was apparent that BMP2 and TSA treatment
resulted in independent gene profiles. While TSA treat-
ment mainly led to a regulation of transcriptional pro-
cesses, BMP2 treatment rather resulted in a regulation
of signal transduction processes. Even though both treat-
ments primarily led to a different expression of genes,
the downregulation of certain genes seems to reflect the
similar phenotype which we had observed in both TSA-
and BMP2-treated neurosphere cultures. While only a
few primary target genes of TSA and BMP2 were clus-
tered within the sub-clusters containing genes regulated
after both treatments, it is obvious that a variety of genes
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the oligodendrocyteproteins Mag (myelin-associated gly-
protein), Mal (myelin and lymphocyte protein), Mog
(myelin oligodendrocyte glycoprotein), Omg (oligoden-
drocyte myelin glycoprotein), Mbp (myelin basic protein),
and Mobp (myelin-associated oligodendrocytic basic
protein), which were downregulated in one or both
treatments.
Since the functional annotation clustering did not dis-
close an enrichment of direct target genes of TSA or
BMP2, and because we detected the strongest overlap of
regulated genes between TSA and BMP2 treatment after
24 h, we decided to perform an additional DAVID
analysis including genes regulated significantly after
different times of treatment. Figure 4 summarizes the
clustered functional categories obtained from TSA 6 h,
TSA 24 h, BMP2 6 h or BMP2 24 h experiment; only
such functional annotation clusters are shown that
possessed a significant enrichment score of 1.5. Gene
Ontology annotations for the clusters can be found in
(Additional file 1: Table S22-S26). The functional categories
obtained after BMP2 6 h treatment included primarily
genes with functions related to developmental processes
(Figure 4C). In contrast, after 24 h treatment a more di-
verse set of functional categories was enriched, possessing
functions in plasma membrane, cell adhesion, antigen-
presenting and developmental processes (Figure 4D). Af-
ter TSA 6 h treatment, categories were enriched which
contained genes with functions in histone modification,
chromatin organization, transcription regulation and cell
cycle control (Figure 4A). Similar to the 24 h BMP2
treatment, the 24 h TSA treatment also showed a more
diverse set of functional categories (Figure 4B). Interest-
ingly, these categories resembled the categories enriched
after BMP2 24 h treatment. This functional overlap is
also reflected in functional annotation clustering of
genes regulated in both BMP2 24 h and TSA 24 h sam-
ples. Clusters with genes involved in functions in plasma
membrane, cell adhesion, cell communication, as well as
genes involved in developmental processes were enriched
(Figure 4E). This suggests that genes regulated after 6 h
directly reflected the well-established activity on gene
regulation mediated by histone deacetylase inhibition,
but that after 24 h already a secondary biological effect
may have been observed.
Validation of the microarray data with
mRNA expression analysis
For validation of the microarray data, we selected several
genes and performed quantitative RT-PCR. Gpr17
(Figure 5G), Bambi (Figure 5H), Smad7 (Figure 5E) and
Bmp4 (Figure 5B) were chosen from the lists of genes
regulated in both TSA and BMP2 treatment. In order to
obtain a more detailed view of the regulatory response,one additional time point and two additional TSA con-
centrations were used (10, 25, or 50nM TSA or 10 ng/ml
BMP2; 6 h, 12 h or 24 h). All selected genes showed
consistent expression patterns in RT-PCR and the micro-
array experiments, although fold-changes determined in
the microarray analysis and the quantitative RT-PCR dif-
fered significantly. In addition to Bambi, Smad7 and
Bmp4, known to be involved in BMP signaling, we de-
cided to analyze the expression of Bmp2 (Figure 5A) and
the BMP target genes Id1 (Figure 5C) and Id2
(Figure 5D). While Bmp4 was downregulated upon TSA
treatment (Figure 5B), the expression of Bmp2 was sig-
nificantly upregulated in a concentration dependent
manner after 6 h, but not after 12 and 24 h (Figure 5A).
Surprisingly, Id1 and Id2 expression was downregulated
at 6 h, but increased after 12 h, resulting in a similar
level of expression compared with BMP2-treated cells
after 24 h, suggesting a partial BMP signaling-independent
effect on Id expression. We furthermore investigated
Stat3 (signal transducer and activator of transcription 3)
(Figure 5F), known to be an upstream regulator of BMP
expression [34] but also to co-regulate astrocyte specific
genes through the formation of a STAT3-p300-Smad
complex [35]. We also decided to analyze Wnt5a (wingless-
related MMTV integration site 5A) (Figure 5I) and
Wisp1 (WNT1 inducible signaling pathway protein 1)
(Figure 5J), both of which are involved in Wnt signal-
ing and are known to act upstream of BMP signaling
[36]. Stat3 (Figure 5F), as well as Wnt5a (Figure 5I) and
Wisp1 (Figure 5J), were significantly upregulated upon
TSA treatment in a time and concentration dependent
manner.
Validation of the microarray data with protein analysis
Based upon the upregulation of Stat3 mRNA expression
(Figure 5F), and its known role in BMP2-triggered astro-
gliogenesis, we performed Western blot analysis of Stat3
and other proteins known to be involved in signaling dur-
ing astrogliogenesis. We investigated the phosphorylation
of Smad1/5/8, known mediators of BMP signaling, Stat3,
and Gsk3-beta, a signaling protein in the canonical Wnt
signaling pathway (Figure 6). Smad1/5/8 was phosphory-
lated in the BMP2 treated samples after 6, 12 and 24 h, but
TSA treatment did not lead to Smad1/5/8 phosphorylation
(Figure 6A). In contrast, pStat3 was strongly induced after
TSA treatment (25nM and 50nM), showing an increase
from 6 h to 24 h, while BMP2 treatment did not induce
Stat3 phosphorylation (Figure 6A). Treatment with TSA
led to a strong reduction of Gsk3-beta phosphorylation
after 24 h, whereas almost no change could be detected
after 6 h and phosphorylation was rather increased after
12 h (Figure 6B). The concentration of pGsk3-beta was
quantified using an ArrayTube™ (Alere Technologies, Jena,
Germany) based sandwich ELISA microarray. Interestingly,
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Figure 4 Functional annotation clustering of BMP2 and TSA treated neurosphere cultures at different time points. Differentially
expressed genes (relative expression >2-fold and absolute difference >100. comparing treated and control sample, confidence >90%) are
functionally clustered using DAVID Database. Functional groups with an enrichment score >1.5 are exhibited. The enrichment score is the
geometric mean (in -log scale) of member's p-values in a corresponding annotation cluster. The number of genes in each cluster is represented
as bars, the corresponding enrichment scores are illustrated as dots. Functional annotation of genes altered in individual treatments with TSA
after 6 h (A) and 24 h (B), BMP2 after 6 h (C) and 24 h (D) as well as of intersectional genes regulated after treatment with BMP2 24 h and TSA
24 h (E) are displayed.
Scholl et al. BMC Genomics 2012, 13:298 Page 10 of 18
http://www.biomedcentral.com/1471-2164/13/298the sandwich ELISA microarray disclosed a clear regula-
tion of Erk2 phosphorylation upon both BMP2 and TSA
treatment (Figure 6C). At the 6 h and 12 h time point
pErk2 was induced in a concentration dependent mannerafter TSA treatment, but also after BMP2 treatment.
After 24 h of treatment the pErk2 signal clearly
decreased, which suggested that pErk2 is involved in the
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Figure 5 Quantitative real-time PCR. Total RNA was extracted from TSA and BMP2 treated neurosphere cultures. Neurosphere cultures were
cultured for 7 days and subsequently dissociated and plated out in monolayers. Cells were treated with TSA (10, 25, 50nM) or 10 ng/μl BMP2
from 1.5-2.5 days after plating. Total RNA was collected 6, 12 or 24 h upon treatment. Reverse-transcript cDNA was analyzed using primer
recognizing the following genes: Bmp2 (A), Bmp4 (B), Id1 (C), Id2 (D), Smad7 (E), Stat3 (F). Gpr17 (G), Bambi (H), Wnt5a (I), Wisp1 (J) and Primer
recognizing beta-Actin and Gapdh were used for normalization. Shown values represent the mean (+/− SEM) of three individual experiments
(6 h and 24 h) or two individual experiments (12 h). * = p< 0.05, ** = p< 0.01, *** = p< 0.001, Student’s T-test.
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We previously demonstrated that treatment of neuronal
precursor cells derived from the ganglionic eminences
(GE) with BMP2 or TSA resulted in a reduction in the
generation of neurons and oligodendrocytes and in an
increase in the production of astrocytes [27]. In this
study, we performed gene expression profiling upon cul-
tures treated with either BMP2 or TSA in order to iden-
tify common genes and signaling pathways regulatingthe differentiation of GE neural precursor cells. The fact
that treatment with BMP2 or TSA resulted in identical
cell fates was reflected in the gene expression data by a
significant overlap of regulated genes. Comparing the
6 h and 24 h experiments, it became obvious that the
overlap of regulated genes between both treatments
increased with the duration of time. After 6 h the gene
expression profile between BMP2 and TSA treatment
differed significantly. Short treatment with TSA resulted
Figure 6 Western Blot and ELISA Microarray. Proteins were extracted from TSA (10, 25, 50nM) and BMP2 (10 ng/μl) treated neurosphere
cultures 6, 12 or 24 h after treatment. Western Blot for pSmad1/5/8, Smad1/5/8, pStat3, Stat3, pGsk3-beta was performed. Beta-Actin was used as
control (A). Phosphorylated proteins were quantified using an ArrayTube™ (Alere Technologies, Jena, Germany) based sandwich ELISA microarray.
Concentration of pGsk3-beta (B) and pErk2 (C) in relation to total protein content is presented.
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modification, drug response, and fundamental cellular
functions, whereas BMP2 treatment led to an early regu-
lation of developmental processes via activation of BMP
signaling. This difference in the early response confirms
the specificity of both treatments. Treatment with the
small molecule inhibitor TSA elicits an induction of stressresponse genes, including heat shock proteins (Hspa1b,
Hspa1a (heat shock protein 1A/B)) [37], oxidative stress
(Gstt3 (glutathione S-transferase, theta 3),Txnip (thioredoxin
interacting protein)) [38,39] and damage response genes
(Ier3 (immediate early response 3), Pmaip1 (phorbol-12-
myristate-13-acetate-induced protein 1)) [40]. A domin-
ant effect of TSA treatment is the regulation of chromatin
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cantly enriched (p-value <10-6). The distribution of GO
groups regulated by TSA is comparable to published
data [41].
After 24 h, both treatments resulted in a more similar
expression profile, not just by an overlap of individual
genes but also through the alteration of several groups
of genes regulating cell communication, cell adhesion
and developmental processes. As shown previously, a
24hour treatment with TSA just before bFGF withdrawal
was sufficient to promote astrogliogenesis and inhibit
the birth of neurons and oligodendrocytes in GE-derived
precursor cultures [27]. Together with the results from
gene expression profiling it can be assumed that a short
treatment with TSA stimulates these cell fate decisions
through epigenetic modification that lead to the up- and
downregulation of the corresponding developmental genes,
though it is also possible that the effect does not occur
at the transcriptional level, but rather through acetyl-
ation of cytoplasmic or nuclear non-histone proteins.
The stronger correlation in the 24 h gene expression
data set between TSA- and BMP2-treated cultures re-
veals that even if the early gene expression response to
the treatment differs dramatically, similar downstream
processes are induced, resulting in a comparable cell fate
phenotype.
BMPs can enhance neurogenesis or gliogenesis de-
pending upon the developmental stage or brain local-
ization. During mid-gestation BMPs are neurogenic [9,10],
whereas in late prenatal and postnatal stages they are
astrogliogenic [5,6]. The data from gene expression pro-
filing revealed however a surprising downregulation of
BMP signaling genes after TSA or BMP2 treatment.
Bmp4 and the receptors Bmpr1a and Bmpr1b were sig-
nificantly downregulated in response to TSA, whereas
BMP signaling inhibitors, like Bambi, Ctgf (connective
tissue growth factor) and Fst, were significantly up-
regulated. Only the BMP signaling inhibitor Smad7 was
significantly downregulated after TSA treatment. This
indicates that both TSA and BMP2 initiate both a direct,
positive response activating the downstream BMP signal-
ing pathway as well as a subsequent negative feedback
loop that results in induction of BMP signaling inhibi-
tors and downregulation of BMP4 and its receptors. This
clear inactivation of further BMP signaling could reflect
the transition between differentiation states, which
requires changes in sensitivity to BMP signals. Sensitivity
to growth factors as well as the duration of signals plays an
important role for BMP- and TGF-beta family signaling
in development. Established mechanisms include select-
ive expression and degradation of receptors and in par-
ticular a range of mechanisms to control the duration
of the signal of activated regulatory Smads (Smad1/5/8,
Smad2/3) through negative feedback mechanisms, includingexpression of inhibitor Smads (Smad6 and Smad7) and de-
phosphorylation and degradation of regulatory Smads [42].
Interestingly, our gene expression profiling did not
show an increase in astrocyte-specific genes. Classic mark-
ers known to be upregulated during astrocyte differenti-
ation were either not regulated (e.g. Gfap (Glial fibrillary
acidic protein)), or were downregulated (e.g. S100ß (S100
protein, beta polypeptide)). This prompted us to look
more closely at the array data and indeed we were able
to identify two transcription factors, Id1 and Id2, whose
expression levels did not significantly change in the array
studies but whose expression was documented to signif-
icantly increase upon either BMP2 or TSA treatment.
BMP2 has previously been shown to cause upregulation
of Id1 and Id2 [43], and forced expression of either gene
can inhibit neurogenesis in telencephalic cultures [8],
suggesting that these two factors play a role in the BMP-
promoted switch from neurogenesis to astrogliogenesis.
In addition, we could demonstrate significant increases
in the mRNA and protein levels of Stat3 and also in its
phosphorylated, transcriptionally active form. This is of
particular relevance for astrogliogenesis as Stat3 has
been shown to functionally interact with the BMP2-
responsive transcription factor Smad1/5/8 at the p300
transcriptional coactivator and thereby synergistically pro-
mote astrogliogenesis [35]. How TSA promotes an
increase in Stat3 levels is unclear at this point, but we
have uncovered evidence that the acetylation of Stat3 is
regulated by TSA-mediated HDAC inhibition (data not
shown).The transient activation of Erk2 in response to
BMP2 and TSA treatment could play a role in the con-
trol of the duration of activated Smad1/5/8 signals. Erk2,
but also other kinases, including Gsk3-beta, are involved
in the control of Smad signals through Smad linker
phosphorylation [44,45]. Phosphorylation of the linker
region by Erk2 and Gsk3-beta targets regulatory Smads
for ubiquitinylation and proteasomal degradation [44,45].
The observed activation of Erk2 should lead to a more
rapid degradation of activated Smads, which can be fur-
ther modulated by Gsk3-beta. Thus, induction of Erk2
by phosphorylation would contribute to termination of
BMP signals [44,45].
Analysis of the genes upregulated in response to TSA
and BMP2 treatment revealed several genes known to be
expressed in neurons. Most of these genes are not mark-
ers or regulators of basic neurogenesis, but are rather
involved in maturation processes or establishment of
the neuronal network, such as neurite outgrowth, axon
guidance and synapse maturation and function. The fact
that we see an upregulation of these genes can be pos-
sibly explained by the developmental age of the cultures,
which were derived from E15.5 GE. At this time point
neurogenesis has reached its peak, before radial glia cells
in GE start to generate astrocytes [46,47]. It is possible
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sion of functional neuronal genes in those precursors
that have already committed to the neuronal fate or have
already been born as neurons. The cultures in our ex-
periments were treated at 2.5 DIV, and a small amount
of neurogenesis has already occurred at this time point
[27]. In addition, it is known that markers of maturing
neurons already begin to be expressed by neuronal pro-
genitors [48,49].
TSA and BMP2 treatment results in a drastic downre-
gulation of genes known to be specific for oligodendro-
cytes, such as Sox10 (SRY-box containing gene 10) and
Nkx2-2 (NK2 transcription factor related, locus 2), a var-
iety of genes involved in myelinization Mag, Mal, Mog,
Omg, Mbp, Mobp, Gm98, and other genes known to be
highly expressed in oligodendrocytes, such as Gpr17,
Bcas1, and Enpp6 [50]. The fact that genes involved in
myelinization were strongly regulated explains the appear-
ance of membrane-related GO terms in the functional
annotation clustering. The downregulation of oligoden-
drocyte specific genes in our experiments is in accord-
ance with a reduction of oligodendrocytes that was
observed by ourselves [27] and others [19]. Many of
these oligodendrocyte specific genes were not only sig-
nificantly down-regulated upon TSA treatment but also
after BMP2 treatment, especially after 24 h. This also
corresponds with previous reports showing that BMPs
promote the production of astroglia while inhibiting
oligodendrocyte differentiation [7]. The fact that treat-
ment with BMP2 and TSA downregulates oligodendro-
cyte specific genes seems to be a common feature of
both compounds, but it still needs to be clarified if the
demonstrated effect is due to the same regulatory mech-
anism. Upregulation of Wnt5a, Wisp1, and other genes
from Wnt signaling in our experiments could give a cer-
tain indication that the regulatory mechanism could be
related in both cases. Wnt signaling leads to the sup-
pression of oligodendrocyte differentiation and promotes
neuronal and astroglial differentiation [51]. The connec-
tion between BMP and Wnt signaling [36] as well as be-
tween HDACs and Wnt signaling [21] had been shown
to be important for astroglial and oligodendroglial line-
age commitment, and it will be of great interest to
examine whether HDACs and BMPs share a common
pathway in the regulation of oligodendrocyte differenti-
ation, as we have shown for astrocyte differentiation in
this work.
Conclusions
In this study we have delineated at the genomic tran-
scriptome level the responses to two different com-
pounds that we and others have shown to lead to similar
biological outcomes in the differentiation of neural pro-
genitor cells to neurons, astrocytes and oligodendrocytesin the embryonic forebrain. Interestingly, the range of
responses to BMP2 and to the global HDAC inhibitor
TSA were dramatically different, with BMP leading to an
upregulation of genes involved in cell-cell communica-
tion and developmental processes while TSA resulted in
an upregulation of genes involved in chromatin modifi-
cation and transcription. Surprisingly, the biological con-
vergence of the genomic responses could not be reduced
to canonical BMP signaling through Smad1/5/8 activa-
tion, rather HDAC inhibition and BMP2 signaling
converge through Stat3 and Smad1/5/8-mediated signal-
ing and Id1 activation which increases astrogliogenesis
from neural stem cells. This result explains the similar
outcomes of HDAC inhibition and BMP with respect to
astrogliogenesis, and the microarray profiling also sug-
gests new pathways, for example Wnt signaling, which
may be of further relevance for the interaction between
these two developmentally-crucial protein families.Methods
Mouse lines
All animal experiments were conducted in compliance
with the regulations of the state of Baden-Württemberg,
Germany. We employed C57BL/6 J mice (Charles River,
Sulzfeld, Germany).Neurosphere cultures
Neurosphere (NS) cultures were prepared from E15.5
GE essentially as described [27]; full protocol described
in [29]. Embryos were dissected on ice in PBS and de-
capitated. The brain was removed, the hemispheres
separated, and the lateral and medial ganglionic emi-
nences removed with fine forceps. GE cells were mech-
anically dissociated with a fire-polished Pasteur pipette and
plated out in cell culture flasks with 100,000 cells per
milliliter (ml) in NS Medium (F12/DMEM (1:1) with
B27 supplement (Invitrogen), penicillin/streptomycin
(100U/ml, Invitrogen), human EGF (20 ng/ml; Sigma)
and human bFGF (10 ng/ml; R&D Systems, Wiesbaden,
Germany). NS were incubated in suspension at 37°C, 5%
CO2 for 1 week and fed on the 5
th day with an equal
volume of NS medium. For differentiation, 7 day-old NS
were collected into 50-ml tubes and centrifuged for 3
minutes at 100xg. The NS were mechanically dissociated
using a fire-polished Pasteur pipette and plated out with
150,000 cells per cm2 in petri dishes (pre-plated with
200 mg/ml polyornithine) in NS medium without EGF
and with 1% fetal calf serum (FCS, Invitrogen), a medium
that supports the differentiation of both neurons and
astrocytes. After 2.5 days of incubation the medium was
changed to NS medium without bFGF and EGF but
with 1% FCS. The following pharmacological reagents
were added in different experiments: 10, 25 or 50nM
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(10 ng/ml), 6 h, 24 h.
Immunocytofluorescence
Neurospheres were cultured as described above, treated
with 50nM trichostatin A, recombinant BMP2 (10 ng/ml),
or both reagents for 24 hours before bFGF withdrawal,
cultured for another 4.5 days, and fixed with 4% PFA for
10 min. Cultures were stained as described [27] with the
following antibodies: TuJ1 (Covance), O4 (kind gift of
Prof. J. Trotter, Mainz, Germany), anti-GFAP (DAKO),
and DAPI (Sigma-Aldrich). Confocal analysis was per-
formed on a Nikon A1Rsi microscope (Nikon Imaging
Center, University of Heidelberg).
RNA Isolation
Total RNA was isolated from neurosphere culture 6, 12,
and 24hours (h) after treatment using RNeasy Mini Kit
(Qiagen) according to the manufacturer’s instructions.
RNA quality was examined by agarose gel electro-
phoreses and concentration was determined by UV ab-
sorbance. Affymetrix Arrays were performed with RNA
samples from untreated and 6 h and 24 h TSA (50nM)
and BMP2-treated cultures. RNA from cultures treated
with TSA (10, 25, or 50nM) or BMP2 (10 ng/ml) from
all three time points were used for quantitative real-
time PCR.
Biotin-labeled cDNA transcription and Affymetrix
gene-chip hybridization
Total RNA samples obtained after 6 h and 24 h treat-
ment were labeled and hybridized to an Affymetrix Gene-
ChipW Mouse Genom 420 2.0 according to manufacturer’s
protocol. Biotin-labled cRNA transcription and Affyme-
trix gene-chip hybridization was performed by the Gen-
omic Core Facility of EMBL, Heidelberg.
Analysis of gene expression data
Raw data obtained from Affymetrix gene-chip were ana-
lyzed using dChip (DNA-chip analyzer) software [31].
Samples were normalized using rank-based (quantile)
normalization [52]. Genes were considered to be signifi-
cantly regulated if expression had changed more than
two-fold and absolute difference of normalized values
exceeded 100 comparing treated and mock-treated
samples with a confidence greater than 90%. Data was
submitted to GEO (Gene Expression Omnibus) [GEO:
GSE31792].
Hierarchical clustering and functional annotation
In order to identify genes that respond similar to BMP2
and TSA treatment, we performed hierarchical cluster-
ing including probe sets regulated as described above
(2-fold change, minimal euclidean distance 100) in anytreatment group. Based on these criteria 2073 probe sets
were included in the hierarchical clustering. The clus-
ter analysis was done using dChip software [31]. Co-
regulated genes identified in the cluster analysis were
functionally annotated using DAVID (Database for An-
notation, Visualization, and Integrated Discovery), a web
based tool for functional annotation of genes according
to the biological process they are involved in [32,33].
Additionally individual functional annotation clustering
was performed with genes significantly regulated in one
treatment group. In both cases genes were uploaded into
DAVID using the web interface. Gene ontology (GO)
terms were obtained including their p-value. GO terms
with p-values< 10-3 were included in the further analysis.
Reverse Transcription and real-time PCR
2 μg of total RNA extracted from neurosphere cul-
tures was reverse transcribed using oligo(dT)18 primer
(0.5 mg/ml, Fermentas) or random hexamer primers
(100 μM, Fermentas) and SuperScript II reverse tran-
scriptase (Invitrogen). Quantitative real-time PCR was
performed on a LightCyclerW 480 (Roche Applied Science)
device using LightCyclerW 480 SYBR Green I Master
with 1 μl cDNA (1:5 dilution of transcribed cDNA). The















The standard quantification protocol was applied with
the following cycles: 1 cycle for preincubation: 5 min at
95°C, followed by 48 cycles for quantification: 10s at
95°C, 10s at 60°C 20s at 72°C. Melting curve analysis
was performed for all samples in order to validate the
unique generation of expected PCR products. In
addition Stat3, Smad7, Bmp2 and Bmp4 expression was
quantified using TaqMan assays (Applied Biosystems,
Mm00456961_m1, Mm00484741_m1, Mm00432087_m1,
Mm01340178_m1, Mm99999915_g1) Primer pairs recog-
nizing beta-Actin or Gapdh were used for normalization.
For statistical analysis, relative expression (RE) levels
were calculated with the function (RE = 2-ΔΔCt), where
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(Ct) number between the control sample or the TSA- or
BMP2-treated sample. Each Ct value was calculated
from triplicate replicates of any given condition. The
mean of relative expression levels were calculated from
the individual RE values from 2–3 independent experi-
ments, and the standard error of the mean (SEM) was
calculated from the standard deviation. In order to eval-
uate the statistical significance the Student’sT-test was
employed, comparing control sample to TSA- or BMP2-
treated samples, respectively.
Immunoblotting
Cells were washed once with room temperature PBS, then
200 μl lysis buffer (1 mM EDTA, 0.5% Triton-X-100, 6 M
urea, in PBS, pH 7.2 - 7.4), complemented with 4%
complete protein inhibitors (Roche), was added per plate.
Cells were scraped from the plates on ice using cell scrapers
(greiner bio-one). Lysates were transferred into eppendorf
tubes, triturated through a syringe (0.80 x 40 mm 21 G,
Braun Sterican) 10 times; the lysates were centrifuged
at 13000 rpm for 12 min at 4°C, aliquoted and stored at
−80°C. Protein concentration was determined via Bradford
assay. Samples were then run on 15% SDS-gels, and blotted
on PVDF-membranes (Millipore). For western blot analysis
following primary antibodies were used: anti-pSmad1
(Ser463/465)/5(Ser463/465)/8(Ser463/465) (Cell Signaling),
anti-Smad1/5/8 (Santa Cruz), anti-pStat3(Tyr705) (Cell
Signaling), anti-Stat3 (Cell Signaling), anti-pGsk3-beta
(Ser9) (Cell Signaling), anti-Mbp (aa82-87) (AbD Sero-
tec), anti-Gfap (DAKO), anti-Plp (aa3) (kind gift of Prof.
J. Trotter, Mainz, Germany), and anti-beta-Actin (Sigma-
Aldrich). As secondary antibody anti-mouse, anti-rat or
anti-rabbit horseradish peroxidase (HRP)-conjugated anti-
bodies (KPL) were used. Protein bands were visualized
with Western Lightning ECL (Perkin Elmer) and detected
with a luminescent image analyzer (LAS-3000, FujiFilm).
For all western blots at least three repetitions were
performed.
ELISA Microarray
Phosphorylated proteins were quantified using an Array-
Tube™ (Alere Technologies, Jena, Germany) based sand-
wich ELISA microarray, as previously described [52]. 10 μl
of protein sample was applied on the microarray. Phos-
phorylated proteins were detected using commercially
available isotype-specific capture antibodies and biotiny-
lated phospho-specific detection antibodies (DuoSets IC
kits, R&D Systems, Minneapolis, USA). For the detection
the microarray was incubated with streptavidin–HRP
conjugate (R&D Systems) followed by dye precipitation
reaction using TrueBlue™ (KPL, Gaithersburg, MD,
USA). Transmission was measured with the Arraymate™
reader (Alere Technologies) and protein concentrationwas quantified using standard calibration surfaces as
described in Holenya et al. [53].
Additional file
Additional file 1: Table S1 - S26. Additional file 1 contains tables with
additional gene expression data. Table S1-S4 summarize the 25 genes
with the strongest regulation of expression after TSA or BMP2 treatment.
Table S5-S10 contains the genes regulated in two treatments, which
represents the intersections of the Venn Diagrams from Figure 3A-F.
Table S11-S21 contains the GO terms obtained from the of hierarchical
cluster analysis (Figure 3G). Table S22-S26 contains the GO terms from
functional annotation cluster (Figure 4A-E) of all genes regulated within
an individual treatment.
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